FindTrial
Sign In

Morning vs evening dosing with tamusuosin in benign prostatic hyperplasia with nocturia patients:Multi-center Randomized Control trial

Morning vs evening dosing with tamusuosin in benign prostatic hyperplasia with nocturia patients:Multi-center Randomized Control trial - RCT on PRO-Dosing

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000004140
Enrollment
100
Registered
2010-08-31
Start date
2009-05-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate hypertrophy

Interventions

dosing in the morning dosing in the evening

Sponsors

Department of Urology Tohoku University School of Medicine
Lead Sponsor
Tohoku Rosai Hospital Ogachi Central Hospital NTT East Sendai Hospital Iwaki Urological Hospital Kesennuma City Hospital Osaki City Hospital Kaneto Urology-Renal Clinic
Collaborator

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: the patients of prostate hypertrophy with nocturia

Exclusion criteria

Exclusion criteria: prostate surgery any co-existing condition that that may affect micturition, such as neurogenic bladder, bladder neck contracture, urethral stricture, urinary tract infection, bladder cancer, or acute or chronic prostatitis bladder stones acute urinary retension residural urine volume of ≥200ml prostate malignancy; or, a prostatic specific antigen of ≥10ng/ml unless biopsy had ruled out prostatic cancer apparent dimentia patient.

Design outcomes

Primary

MeasureTime frame
number of night time voiding episode—

Secondary

MeasureTime frame
IPSS IPSS QoL—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026